Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Files An 8-K Regulation FD Disclosure

52

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Files An 8-K Regulation FD Disclosure

Item 7.01, including Exhibit 99.1 attached hereto, is being
furnished and shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the
Exchange Act) or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference
in such a filing.

Item
9.01
.

Financial Statements and Exhibits.

Exhibit No.

Description

99.1

Progenics Pharmaceuticals, Inc. Investor Presentation dated
June 19, 2017



PROGENICS PHARMACEUTICALS INC Exhibit

To view the full exhibit click here
About Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)

Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company’s products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases. The Company’s EXINI Bone BSI is an analytical tool that employs an artificial intelligence-based approach to apply techniques of statistical analysis and pattern recognition to quantify the information produced by bone scintigraphy (bone scan) images used to view cancer present in the skeleton. The EXINI Bone BSI tool reads bone scans and produces an automated Bone Scan Index quantification. The Company’s clinical-stage products include AZEDRA, 1404 (trofolastat), PyL ([18F] DCFPyL), 1095 and PSMA ADC. The Company’s partnered products include Relistor-Subcutaneous injection, Relistor-Oral Tablets and PRO 140.

An ad to help with our costs